National Vision (EYE)
(Delayed Data from NSDQ)
$9.98 USD
+0.29 (2.99%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $9.99 +0.01 (0.10%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$9.98 USD
+0.29 (2.99%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $9.99 +0.01 (0.10%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth F Momentum B VGM
Zacks News
National Vision (EYE) Down 6.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Implied Volatility Surging for National Vision (EYE) Stock Options
by Zacks Equity Research
Investors need to pay close attention to National Vision (EYE) stock based on the movements in the options market lately.
Prestige Consumer's (PBH) Q1 Earnings Beat, Margins Shrink
by Zacks Equity Research
Prestige Consumer (PBH) first-quarter sales bear the brunt of the ongoing supply chain challenges in the Clear Eyes business.
Insulet (PODD) Q2 Earnings Miss Estimates, '24 Sales View Raised
by Zacks Equity Research
Insulet's (PODD) second-quarter performance benefits from the continued high demand for Omnipod 5.
National Vision (EYE) Tops Q2 Earnings, Lowers '24 Outlook
by Zacks Equity Research
National Vision (EYE) delivers an earnings beat in the second quarter of 2024 and announces new transformative actions for long-term growth.
National Vision (EYE) Q2 Earnings Beat Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 150% and 2.83%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Should Value Investors Buy National Vision (EYE) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
EYE vs. PODD: Which Stock Is the Better Value Option?
by Zacks Equity Research
EYE vs. PODD: Which Stock Is the Better Value Option?
Will WATCHMAN Sales Aid Boston Scientific's (BSX) Q2 Earnings?
by Zacks Equity Research
In EMEA, Boston Scientific (BSX) is expected to have registered growth within structural heart, including Transcatheter aortic valve replacement, WATCHMAN and other interventional cardiology therapies.
Is a Beat Likely for Edwards Lifesciences (EW) in Q2 Earnings?
by Zacks Equity Research
Edwards Lifesciences' (EW) TMTT segment's PASCAL platform is likely to have maintained strong growth momentum in the second quarter globally, backed by its portfolio of differentiated therapies.
Are Investors Undervaluing National Vision (EYE) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Strength Seen in National Vision (EYE): Can Its 7.2% Jump Turn into More Strength?
by Zacks Equity Research
National Vision (EYE) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
EYE or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EYE vs. SYK: Which Stock Is the Better Value Option?
National Vision (EYE) Gains Market Share Despite Macro Woes
by Zacks Equity Research
National Vision (EYE) continues to execute core growth initiatives and further invest in strengthening competitive advantages.
National Vision (EYE) Down 4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
National Vision (EYE) Q1 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
National Vision (EYE) delivers improved revenues in the first quarter of 2024 in a challenging macro environment.
National Vision (EYE) Q1 Earnings Top Estimates
by Zacks Equity Research
National Vision (EYE) delivered earnings and revenue surprises of 7.14% and 2.68%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Jushi Holdings Inc. (JUSHF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Jushi Holdings Inc. (JUSHF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: National Vision (EYE) Q1 Earnings Expected to Decline
by Zacks Equity Research
National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
National Vision (EYE) Down 4.1% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
National Vision (EYE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Retain National Vision (EYE) Stock Now
by Zacks Equity Research
The strong execution of strategic initiatives and robust financial stability bode well for National Vision (EYE).
National Vision (EYE) Q4 Earnings Top Estimates, Margins Fall
by Zacks Equity Research
National Vision's (EYE) Q4 adjusted comparable store sales growth is driven by ongoing strength within America's Best and Eyeglass World sales.
Stock Market News for Feb 28, 2024
by Zacks Equity Research
Wall Street closed with a mixed performance on Tuesday as investors awaited crucial inflation data, which could influence the Federal Reserve's interest rate decisions.
National Vision (EYE) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for National Vision (EYE) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Countdown to National Vision (EYE) Q4 Earnings: Wall Street Forecasts for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of National Vision (EYE) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.